Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00884507 · ClinicalTrials.gov registry record · Phase 2
A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 389
- Enrollment target
NCT00884507: Completed Phase 2 study, sponsored by Hoffmann-La Roche.
NCT00884507 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 389 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (192% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00884507, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 389 participants
- Enrollment target
Study Summary
This 4 arm study will assess the efficacy and safety of RO5313534 (MEM3454) versus placebo added to donepezil, in patients with mild to moderate Alzheimer's disease. Following a screening period, patients will be randomized to one of 4 treatments (placebo, or RO5313534 1mg, 5mg or 15mg po daily) with background therapy of donepezil (5mg or 10mg).The anticipated time on study treatment is 6 months, and the target sample size is 100-500 individuals.
Interventions
- DRUG Placebo
- DRUG RO5313534
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 389 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
What the finished NCT00884507 record still lists
NCT00884507 is an interventional study that assigns participants to a tested intervention. The registered 389 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (192% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00884507 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00884507 about?
NCT00884507 is a clinical study titled "A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease". This 4 arm study will assess the efficacy and safety of RO5313534 (MEM3454) versus placebo added to donepezil, in patients with mild to moderate Alzheimer's disease. Following a screening period, patients will be randomized to one of 4 treatments (placebo, or RO5313534 1mg, 5mg or 15mg po daily) wit...
What is the current status of trial NCT00884507?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 389 participants. The study started on 2009-05. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00884507?
The interventions under investigation include: Placebo (DRUG), RO5313534 (DRUG).
Who is sponsoring clinical trial NCT00884507?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00884507's enrollment target sits among peer trials
389 108th of 2000 higher than 1,892 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05431088 · 389 participants · Phase 2
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
- NCT00397111 · 390 participants
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
- NCT05335928 · 390 participants · Phase 3
Abatacept in Immune Checkpoint Inhibitor Myocarditis
- NCT05445960 · 390 participants · NA
Correlation Between Intraoperative Tourniquet Use and Limb pH, Functional Measures and Patient-reported Outcomes After Ankle Fracture Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia